Drug intelligence / Profile preview

VigaPlus

Development stage: Unknown
Lead developer: Vitofarma
Modality: Small Molecules
Administration: Oral

Overview

VigaPlus is an herbal dietary supplement developed by Vitofarma, specifically indicated for the management of erectile dysfunction and the enhancement of male sexual vigor. The formulation typically leverages traditional Peruvian medicinal plants, most notably Maca (Lepidium meyenii) and Huanarpo Macho (Jatropha macrantha). These ingredients are believed to function by promoting nitric oxide synthesis, which enhances vasodilation and blood flow to the corpus cavernosum, and by modulating hormonal pathways to improve libido and stamina. It is marketed as a natural alternative to synthetic phosphodiesterase type 5 (PDE5) inhibitors.

Brand names: VigaPlus
Other names: VigaPlus

Targets

NOS1 (nNOS)AR (Adrenergic receptors)

Beyond the preview

Go deeper on VigaPlus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VigaPlus.

Explore the full profile